Jci_page_head_homepage_01 Jci_page_head_homepage_02
Robert A. Hegele, Karen Reue
Published in Volume 119, Issue 2
J Clin Invest. 2009; 119(2):249–251 doi:10.1172/JCI38420
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1
Proposed model for distinct hepatic insulin resistance (IR) phenotypes resulting from INSR and AKT2 gene mutations.

(A) Under normal circumstances, insulin stimulation of the INSR activates apparently independent arms of the signaling pathway: (i) AKT2 activation, phosphorylation of FOXO1, and inhibition of gluconeogenic gene transcription, leading to decreased glucose output, and (ii) activation of SREBP-1c target lipogenic genes, leading to secretion of triglyceride-rich VLDLs (VLDL TG). (B) Mutation in INSR prevents activation of both arms of the pathway, resulting in increased glucose levels without increased TG levels. (C) Mutation in the AKT2 gene impairs inhibition of gluconeogenesis without abolishing the lipogenic effect of insulin, resulting in increased glucose and TG levels. ACC, acetyl-coenzyme A carboxylase; FAS, fatty acid synthase; PEPCK, phosphoenolpyruvate carboxykinase.